Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-2089 in Immune Thrombocytopenia
NCT07095127Phase 2Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Fragments, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NVG-2089 in immune thrombocytopenia (ITP), sponsored by Biohaven Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
NVG-2089
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07095127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095127.